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June 20091634 Letters to the EditorRegarding “National outcomes for the treatment of
ruptured abdominal aortic aneurysm: Comparison of
open versus endovascular repairs”
Egorova et al1 showed an increased survival after ruptured
abdominal aortic aneurysm (RAAA) of patients who were treated
with endovascular aortic repair (EVAR) as compared with those
treated with open aortic repair (OAR): adjusted hazard ratio (HR),
0.857; 95% confidence interval (CI), 0.768 to 0.957; P  .0061;
for patients matched by propensity score (n  2,088). To our
knowledge, there has been only one randomized controlled trial2
of EVAR versus OAR for RAAA. Meanwhile, although a lot of
observational comparative studies reported mortality, odds ratios
(ORs), or HRs, most of them are not adjusted but crude ones. In
an attempt to correct for and minimize selection bias that exists in
observational studies, we previously performed a meta-analysis
pooling not crude but adjusted ORs (representing 6,097 patients)
and demonstrated no benefit of EVAR over OAR for mortality in
RAAA (pooled OR, 0.71; 95% CI, 0.41 to 1.22; P  .21).3 We
herein updated our previous meta-analysis3 of randomized con-
trolled trials and high-quality (reporting adjusted ORs or HRs for
mortality) observational comparative studies (including the study
by Egorova et al1).
Our comprehensive search identified one randomized con-
trolled trial2 and six (two prospective4,5 and four retrospective1,6-8)
high-quality (reporting adjusted ORs or HRs) observational
comparative studies. We excluded observational comparative
studies reporting only crude mortality, ORs, or HRs. Pooled
analysis of the OR from the randomized controlled trial and the
adjusted ORs from the observational comparative studies (rep-
resenting 18,116 patients; 2,382 in the EVAR group and
15,734 in the OAR group) demonstrated a statistically signifi-
cant 23% reduction in mortality with EVAR relative to OAR in
a random-effects model (pooled OR, 0.77; 95% CI, 0.64 to
0.93; P  .007) (Fig). There was significant between-study
heterogeneity of results analyzed by means of standard 2 tests
(P  .04) but no evidence of significant publication bias as-
sessed mathematically using an adjusted rank-correlation test
(P  .45).
The present meta-analysis of one randomized controlled trial
and six high-quality (reporting adjusted ORs or HRs) observa-
tional comparative studies demonstrated significant benefit of
EVAR over OAR for mortality in RAAA, which strengthened the
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Hisato Takagi, MD, PhD
Hideaki Manabe, MD
Norikazu Kawai, MD
Shin-nosuke Goto, MD
Takuya Umemoto, MD, PhD
Department of Cardiovascular Surgery
Shizuoka Medical Center
Shizuoka, JapanFig. Forest plot of adjusted odds ratiosREFERENCES
1. Egorova N, Giacovelli J, Greco G, Gelijns A, Kent CK, McKinsey JF.
National outcomes for the treatment of ruptured abdominal aortic
aneurysm: comparison of open versus endovascular repairs. J Vasc Surg
2008;48:1092-100, 1100.e1-2.
2. Hinchliffe RJ, Bruijstens L,MacSweeney ST, Braithwaite BD. A random-
ised trial of endovascular and open surgery for ruptured abdominal aortic
aneurysm - results of a pilot study and lessons learned for future studies.
Eur J Vasc Endovasc Surg 2006;32:506-15.
3. Takagi H, Kawai N, Umemoto T. Regarding “Endovascular repair of
ruptured abdominal aortic aneurysms”. J Vasc Surg 2008;48:253-4;
author reply 254-5.
4. Peppelenbosch N, Geelkerken RH, Soong C, Cao P, Steinmetz OK,
Teijink JA, et al. Endograft treatment of ruptured abdominal aortic
aneurysms using the Talent aortouniiliac system: an international multi-
center study. J Vasc Surg 2006;43:1111-23.
5. Moore R, Nutley M, Cina CS, Motamedi M, Faris P, Abuznadah W.
Improved survival after introduction of an emergency endovascular ther-
apy protocol for ruptured abdominal aortic aneurysms. J Vasc Surg
2007;45:443-50.
6. Larzon T, Lindgren R, Norgren L. Endovascular treatment of ruptured
abdominal aortic aneurysms: a shift of the paradigm? J Endovasc Ther
2005;12:548-55.
7. Greco G, Egorova N, Anderson PL, Gelijns A, Moskowitz A, Nowygrod
R, et al. Outcomes of endovascular treatment of ruptured abdominal
aortic aneurysms. J Vasc Surg 2006;43:453-9.
8. Lesperance K, Andersen C, Singh N, Starnes B, Martin MJ. Expanding
use of emergency endovascular repair for ruptured abdominal aortic
aneurysms: disparities in outcomes from a nationwide perspective. J Vasc
Surg 2008;47:1165-71.
doi:10.1016/j.jvs.2008.11.126
Reply
We appreciate the support for our data from the writers. We
agree that in order to reach valid and clinically significant conclu-
sions utilizing observational data, investigators must reach beyond
crude estimates and strive to adjust for possible variables that might
confound their conclusion. In this analysis, to control for patient,
hospital, and surgeon characteristics, a propensity model was de-
veloped and patients undergoing open repair were matched to
those undergoing endovascular abdominal aortic aneurysm repair
(EVAR) by their propensity score. In this way we controlled for
selection bias by constructing a propensity score. This method
resulted in two matched cohorts similar in all variables and allowed
confidence in our conclusion that the outcome of decreased mor-
tality can be attributed to the endovascular approach to ruptured
aortic aneurysms. We feel that, in order to more accurately reflect
the comparison of two technologies for treating a given disease
process, the use of randomized trials or propensity scores for
nonrandomized trials are critical for accurate data analysis. We
appreciate the validation of our data analysis by this meta-analysis.for mortality of included studies.
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Regarding “Statins are independently associated with
reduced mortality in patients undergoing
infrainguinal bypass graft surgery for critical limb
ischemia”
Schanzer et al1 demonstrated in their nonrandomized obser-
vational study that preoperative (at time of hospital admission)
statin use was not associated with reduced 30-day adjusted (pro-
pensity model weighting) mortality (2.2% in the statin group
versus 2.7% in the no statin group) in patients undergoing infrain-
guinal bypass graft surgery for critical limb ischemia. Meanwhile, a
meta-analysis (not including the study by Schanzer et al1) by
Hindler et al2 demonstrated that preoperative statin therapy sig-
nificantly reduced postoperative short-term (30-day) mortality in
patients undergoing vascular surgery (pooled odds ratio [OR],
0.41; 95% confidence interval [CI], 0.27 to 0.61; P  .0001).
Hindler et al,2 however, pooled not adjusted but crude ORs for
mortality in nonrandomized observational studies. In an attempt
to correct for and minimize selection bias that exists in nonran-
domized observational controlled studies, we herein performed a
meta-analysis pooling ORs in randomized controlled trials and
adjusted ORs in nonrandomized observational studies (including
the study by Schanzer et al1) of preoperative statin therapy for
prevention of postoperative short-term (in-hospital or 30-day)
mortality in patients undergoing vascular surgery.
Our comprehensive search identified one randomized con-
trolled trial3 and five high-quality (reporting adjusted mortality or
ORs) nonrandomized observational studies (one prospective co-
hort,4 three retrospective cohort,1,5,6 and one case-controlled7).
We excluded nonrandomized observational studies reporting only
crude mortality or ORs. Vascular surgery included abdominal
aortic repair,3,4,7 lower extremity revascularization,1,3,4,7 and ca-
rotid endarterectomy.3,4-7 Kennedy et al6 reported adjusted ORs
separately in asymptomatic and symptomatic patients undergoing
carotid endarterectomy. Pooled analysis of the OR in the random-
ized controlled trial and the adjusted ORs in the nonrandomized
observational studies (representing 7,344 patients; 3,275 in the
statin group and 4,069 in the no statin group) demonstrated a
statistically significant 68% reduction in short-term mortality with
satin therapy in a random-effects model (pooled OR, 0.32; 95%
CI, 0.16 to 0.62; P  .0008) (Fig). There was neither between-
study heterogeneity of results analyzed by means of standard 2
tests (P .08) nor evidence of significant publication bias assessedFig. Forest plot of adjusted odds ratiosmathematically using an adjusted rank-correlation test (P  .88).
Sensitivity analyses were performed to assess the contribution of
each study to the pooled estimate by excluding individual studies
one at a time and recalculating the pooled OR estimates for the
remaining studies. In general, exclusion of any single study from
the analysis did not substantively alter the overall result of our
analysis.
Despite the results of the study by Schanzer et al,1 the present
meta-analysis of one randomized controlled trial and five high-
quality (reporting adjusted mortality or ORs) nonrandomized
observational studies demonstrated significant benefit of preoper-
ative statin therapy for postoperative short-term mortality in pa-
tients undergoing vascular surgery.
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